Cell Isolation Market

Cell Isolation Market Size, Share & Trends

The cell isolation market is expected to generate a revenue of USD 8.4 billion by 2029, with a revenue of USD 4.6 billion in 2024 to register a CAGR of 12.9%. The growth of the market can be attributed to the growing focus on technology advancement along with the development of new products that are more economical, technologically advanced, and easy to use. In the past 3 years, key players have launched various cell isolation products such as the next-generation platform of Gibco CTS Detachable Dynabeads (Thermo Fisher Scientific Inc.), BD FACSDiscover S8 cell sorter (BD), CultureOne Maxi (ALFA LAVAL), among others. The launch of these systems is expected to increase their adoption for cell isolation. Furthermore, research activities and funding availability by the government for cell-based research have increased as newer and better treatments for chronic diseases including autoimmune, neurological, and cardiovascular disorders become more necessary. This funding for cell-based research is likely to boost the growth of the market. In addition, various other factors including a surge in cases of cancer and infectious diseases, a growing focus on personalized medicine and next-generation therapeutics are further likely to boost the market growth.

Cell Isolation Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Cell Isolation Market

Global Cell Isolation Market Dynamics

DRIVER: Increasing government funding for cell-based research

Cell isolation is mostly used to create new cell therapies and other cell-based treatments. Because of the importance of cell-based research, various government organizations around the world have increased their support for such programs. For example, in June 2024, the National Institute of Neurological Disorders and Stroke awarded the University of Buffalo scientists a five-year grant of approximately USD 2.9 million for a research project aimed at developing a new technology that could improve stem cell therapies for multiple sclerosis (MS) and other neurological diseases.

RESTRAINT: High cost of cell-based research

Cell biology researchers are conducting extensive research to develop new therapies, including gene and stem cell therapies. To obtain accurate results, the instruments, reagents, and other products used in this research must be of high quality, resulting in high cost.

According to a blog published byExcedr 2024, the cost of flow cytometer systems is determined by their component and feature sets. Although some manufacturers, such as Sony Biotechnology Inc (US), are beginning to create flow cytometers for less than USD 100,000, the cost of a single instrument can still range from USD 100,000 to USD 500,000. Furthermore, the cost of conducting cell biology research is significant due to the need to follow regulatory guidelines and maintain high-quality standards. Furthermore, the success rate of cell-based research is extremely restricted, as the majority of cell therapy trials have a low success rate.

OPPORTUNITY: Increasing focus on next-generation therapeutics

Given the widespread success of COVID-19 vaccines, such as mRNA vaccines, the future of protein therapies has gained significant importance. Next-generation protein treatments include tailored antibodies, bi/multi-specific compounds, antibody mimics/novel scaffolds, and ligand/receptor engineers. These novel therapy approaches aim to improve therapeutic efficacy in a variety of diseases by utilizing a wide range of biologics. Promising accurate and successful treatments for diseases such HIV and dementia, antimicrobial medicines include immune-drug combos and immunological mimics such adhirons epitomize the variety in this research. Particularly in complicated diseases with limited therapeutic efficacy, next-generation protein therapeutics show great promise for transforming therapeutic methods with advances in structural biology and recombinant biologics. For example, Evaluate Pharma's (May 2023) statistics show that over 500 ADC medication candidates are now under development. Of these, more than 90% are preclinical in nature.

CHALLENGE: Technical complexities and standardization issues

The market is challenged by technological complexity and standardizing problems, therefore impeding its expansion. The complexity of cell isolation methods including magnetic isolation and flow cytometry demands specialized knowledge and sophisticated equipment, therefore restricting the advanced possibilities of small labs and hospitals. The need for specialized equipment, constant maintenance of such equipment, and the lengthy production time for novel technologies and treatments can all result in increased operational costs. As regulatory requirements are constantly changing and highly variable, standardization efforts are hampered significantly. Furthermore, the lack of standard protocols makes cell separation processes challenging in industrial and therapeutic situations where consistent quality and outcomes are required. As a result, a lack of consistency may result in disparities between research and clinical applications.

Global Cell Isolation Ecosystem Analysis

The cell isolation market ecosystem consists of raw material suppliers, cell isolation product manufacturers, and end users such as pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, and other end users. Cell isolation products manufacturers provide consumables and instruments.

The consumables segment dominated the cell isolation industry in 2023

Based on products, the cell isolation market is segmented into consumables and instruments. The consumables segment is further categories into reagents, kits, media & sera, beads, and disposables. Additionally, beads are categorized into magnetic beads and fluorescent beads. The instrument segment is divided into centrifuges, cell sorters, magnetic-activated cell separator systems, and filtration systems. The consumables segment held the highest position in the market in 2023, due to the high demand for high-quality consumables for biopharmaceutical manufacturing.

The adipose tissue segment dominated the cell isolation industry in 2023

Based on the cell source, the cell isolation market is categorized into adipose tissue, bone marrow, cord blood/embryonic stem cells, and other cell sources. Adipose tissue accounted for the majority of the global market in 2023 due to its widespread use in tissue engineering products. Adipose tissue's potential for cell-based therapies and tissue engineering applications is further influenced by factors such as its ease of access, abundance of therapeutic stem cells, immunomodulatory properties, and regenerative capacity.

North America dominated the cell isolation industry in 2023

The global cell isolation market is divided into six primary regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America led the cell isolation market in 2023, followed by Europe and Asia Pacific. Several reasons contribute to this strong position, such as the well-established healthcare business, substantial investments in research and development activities, and expanded development and production of cell-based drugs.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the cell isolation market include Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), BD (US), Agilent Technologies, Inc. (US), Miltenyi Biotec (Germany), Revvity (US), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Lonza (Switzerland), QIAGEN (Netherlands), ALFA LAVAL (Sweden), Terumo Corporation (Japan), Corning Incorporated (US), Bio-Rad Laboratories, Inc. (US), GenScript (US), Bio-Techne (US), Takara Bio Inc. (Japan), Standard BioTools (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), and STEMCELL Technologies (Canada).

Scope of the Cell Isolation Industry:

This report categorizes the cell isolation market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Consumables
  • Reagents, Kits, Media & Sera
  • Beads
    • Magnetic Beads
    • Fluroscent Beads
  • Disposables
• Instruments
  • Centrifuges
  • Cell Sorters
  • Magnetic-activated Cell Seperator Systems
  • Filtration Systems

By Cell Type

• Human Cells
  • Differentiated Cells
  • Stem Cells
• Animal Cells

By Cell Source

• Adipose Tissues
• Bone Marrow
• Cord Blood/ Embryonic Stem Cells
• Others

By Technique

• Centrifugation-based Cell Isolation
• Surface-based cell Isolation
• Filtration-based Cell Isolation

By Application

• Biomolecule Isolation
• Cancer Research
• Stem Cell Research
• Tissue Regeneration & Regenerative Medicine
• In-vitro Diagnostics
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Diagnostic Laboratories
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East
  • GCC Countries
    • Saudi Arabia (KSA)
    • United Arab Emirates (UAE)
    • Rest of GCC Countries (RoGCC)
  • Rest of Middle East (RoME)
• Africa

Recent Developments of Cell Isolation Industry:

• In April 2024, Merck KGaA invested over USD 300 million (Euro 300 million) in a new research center at Darmstadt. This advanced research center will focus on developing solutions for antibody manufacturing, mRNA applications, and other biotechnological production needs.
• In September 2023, Thermo Fisher Scientific Inc. launched a next-generation platform of Gibco CTS Detachable Dynabeads, which features an active release mechanism to enable process flexibility, scalability, and cost savings while delivering high cell purity, yield, and viability, accelerating the development and commercialization of cell therapies.
• In March 2023, Danaher Corporation partnered with the University of Pennsylvania to develop technologies for improving the consistency of clinical outcomes for patients and overcoming manufacturing bottlenecks in the delivery of next-generation engineered cell therapies.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst